Pharmaceuticals, Biotechnology & Life Sciences

Cho Dennis sells Twist Bioscience shares on a pre‑planned Rule 10b5‑1 plan, a routine portfolio move amid a strong insider‑buying backdrop.

Regeneron insider trades show EVP Joseph Larosa buying low and selling near market highs, hinting at confidence in long‑term prospects while securing liquidity for potential strategic moves.

Tempus AI insider sales are routine “sell‑to‑cover” trades, not a sign of risk—insiders keep their bets on the AI‑driven oncology platform.

Insider buying spree at Amylyx Pharma shows CEO Klee’s confidence in avexitide’s NDA success, hinting at a short‑term rally for investors.

Insider trading at Viridian Therapeutics shows CEO Jennifer Tousignant buying and selling shares— a bullish signal of confidence in the biotech’s growth and upcoming milestones.

Insider sales at Nektar Therapeutics reveal routine tax‑planning, not a confidence dip – learn why executives are selling now and what it means for investors.

Insider sales flood Skye Bioscience ahead of a reverse split and pending Redx Pharma deal – a red flag for investors amid sharp price swings.

Robert Hershberg’s recent $6.32 buy‑back of 15,000 Adaptive Biotechnologies shares signals insider confidence and a potential upside, but investors should weigh the company’s earnings outlook and market volatility.

Insider selling at Rocket Pharma shows steady, tax‑driven RSU sales—no red flag yet, but investors should watch cumulative volume for liquidity clues.

Arrowhead insider sale: Director Olukotun Adeoye sells 2,000 shares amid a 2.2% weekly gain, sparking questions on confidence and future growth in the gene‑silencing biotech sector.